Genocea Biosciences, Inc. – NASDAQ:GNCA

Add to watchlist

$0.001

Market closed

Open in 1 day

-90.00%

month

-93.15%

quarter

-99.90%

year

Market Cap	N/A
Enterprise value	N/A

P/E	N/A
EV/Sales	-2.43
EV/EBITDA	0.12
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-0.55

Revenue	N/A
EBITDA	-37.19M
Income	-39.26M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-1946.15%
Oper. margin	-2901.31%
Gross margin	0%
EBIT margin	-2901.31%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Genocea Biosciences, Inc. (NASDAQ:GNCA): Profit margin
Jun 2021	0	-4.31M
Sep 2021	1.64M	-3.62M	-220.72%
Dec 2021	-1.64M	-15.12M	921.57%
Mar 2022	270K	-16.20M	-6003.33%

Genocea Biosciences, Inc. (NASDAQ:GNCA): Debt to assets
Jun 2021	77383000	73.32M	94.76%
Sep 2021	64918000	27.08M	41.73%
Dec 2021	55967000	28.89M	51.62%
Mar 2022	38788000	26.40M	68.07%

Genocea Biosciences, Inc. (NASDAQ:GNCA): Cash Flow
Jun 2021	-10.51M	-714K	5.59M
Sep 2021	-11.36M	-530K	399K
Dec 2021	-11.10M	-920K	265K
Mar 2022	-15.20M	-939K	-863K

Genocea Biosciences alternative data

Genocea Biosciences, Inc. (NASDAQ:GNCA): Employee count
Aug 2023	74
Sep 2023	74
Oct 2023	74
Nov 2023	74
Dec 2023	74
Jan 2024	74
Feb 2024	74
Mar 2024	74
Apr 2024	74
May 2024	74
Jun 2024	74
Jul 2024	74

Genocea Biosciences
Insider Trading

Genocea Biosciences, Inc. (NASDAQ:GNCA): Insider trades (number of shares)
Period	Buy	Sel
Mar 2022	0	22771
Apr 2022	0	8153
May 2022	0	178601
Jun 2022	0	9456

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	2 Jun 2022	CLARK WILLIAM D director, officer: President and CEO director, officer: President an..	Common Stock	4,023	$0.06	$241
Sale	2 Jun 2022	FLECHTNER JESSICA BAKER officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	1,578	$0.06	$95
Sale	2 Jun 2022	DUVALL DIANTHA officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Common Stock	1,355	$0.06	$81
Sale	1 Jun 2022	SUMER JACQUELYN L officer: CHIEF LEGAL & COMPLIANCE OFF officer: CHIEF LEGAL & COMPLIAN..	Common Stock	2,500	$0.06	$150
Sale	31 May 2022	CLARK WILLIAM D director, officer: President and CEO director, officer: President an..	Common Stock	117,244	$0.06	$7,269
Sale	27 May 2022	SIBER GEORGE director director	Common Stock	20,425	$0.07	$1,328
Sale	26 May 2022	DUVALL DIANTHA officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Common Stock	24,407	$0.08	$1,879
Sale	25 May 2022	FLECHTNER JESSICA BAKER officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	16,525	$0.09	$1,454
Sale	4 Apr 2022	FLECHTNER JESSICA BAKER officer: Chief Scientific Officer officer: Chief Scientific Officer	Common Stock	1,212	$1.25	$1,515
Sale	4 Apr 2022	DUVALL DIANTHA officer: CHIEF FINANCIAL OFFICER officer: CHIEF FINANCIAL OFFICER	Common Stock	963	$1.25	$1,204

GNCA insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application TREATMENT METHODS Filling date: 15 May 2020 Issue date: 7 Jul 2022	15 May 2020	7 Jul 2022
Grant	Grant Utility: Vaccines and compositions against Streptococcus pneumoniae Filling date: 17 Sep 2018 Issue date: 28 Dec 2021	17 Sep 2018	28 Dec 2021
Application	Application TREATMENT METHODS Filling date: 2 Apr 2021 Issue date: 4 Nov 2021	2 Apr 2021	4 Nov 2021
Grant	Grant Utility: Antigen screening system Filling date: 16 Jan 2020 Issue date: 2 Nov 2021	16 Jan 2020	2 Nov 2021
Application	Application TREATMENT METHODS Filling date: 30 Oct 2020 Issue date: 1 Jul 2021	30 Oct 2020	1 Jul 2021
Application	Application ANTIGEN SCREENING SYSTEM Filling date: 16 Jan 2020 Issue date: 10 Dec 2020	16 Jan 2020	10 Dec 2020
Grant	Grant Utility: Treatment methods Filling date: 20 Mar 2018 Issue date: 8 Dec 2020	20 Mar 2018	8 Dec 2020
Grant	Grant Utility: Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response Filling date: 3 Jan 2018 Issue date: 19 May 2020	3 Jan 2018	19 May 2020
Grant	Grant Utility: Antigen screening system Filling date: 19 Dec 2017 Issue date: 25 Feb 2020	19 Dec 2017	25 Feb 2020

Genocea Biosciences
Earnings Call Transcripts

Quarter	Transcript
Q4 2021 10 Mar 2022	Q4 2021 Earnings Call Transcript
Q3 2021 28 Oct 2021	Q3 2021 Earnings Call Transcript
Q2 2021 29 Jul 2021	Q2 2021 Earnings Call Transcript
Q1 2021 29 Apr 2021	Q1 2021 Earnings Call Transcript

GNCA earnings call transcripts

Genocea Biosciences
Executives

Insider	Age	Compensation
Mr. William D. Clark M.B.A. (1969) Pres, Chief Executive Officer & Director	56	$821,390
Dr. Thomas A. Davis (1964) Chief Medical Officer	61	$631,720
Dr. Girish N. Aakalu Ph.D. (1975) Chief Bus. Officer	50	$536,420

Genocea Biosciences
Latest News

Wednesday, 25 May 2022
10:38	Genocea Biosciences Is Shutting Down. What GNCA Stock Investors Should Know.	InvestorPlace
Monday, 11 April 2022
09:36	Best Penny Stocks Right Now? 3 to Watch as HOTH Stock Explodes	PennyStocks
Friday, 8 April 2022
14:35	Genocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor Patients	Benzinga
Monday, 14 March 2022
17:06	Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference	GlobeNewsWire
Thursday, 10 March 2022
10:25	Genocea Biosciences, Inc. (GNCA) CEO William Clark on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Tuesday, 8 March 2022
17:39	Genocea to Present Clinical and Preclinical Data at AACR Annual Meeting	GlobeNewsWire
Thursday, 3 March 2022
08:00	Genocea to Host Fourth Quarter 2021 Corporate Update Conference Call & Webcast	GlobeNewsWire
Thursday, 10 February 2022
19:50	Genocea to Present at the 11th Annual SVB Leerink Global Healthcare Conference	GlobeNewsWire
Wednesday, 5 January 2022
17:46	Genocea to Present at Upcoming Investor Conferences	GlobeNewsWire
Wednesday, 10 November 2021
19:26	Genocea to Present at the Stifel 2021 Virtual Healthcare Conference	GlobeNewsWire
Thursday, 28 October 2021
13:29	Genocea Biosciences' (GNCA) CEO Chip Clark on Q3 2021 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 21 October 2021
16:30	Genocea to Host Third Quarter 2021 Corporate Update Conference Call & Webcast	GlobeNewsWire
Tuesday, 28 September 2021
16:30	Genocea to Present at Upcoming Conferences	GlobeNewsWire
Monday, 13 September 2021
16:52	Jennifer Herron, of ADC Therapeutics, Joins Genocea Biosciences' Board of Directors	GlobeNewsWire
Tuesday, 7 September 2021
19:40	Genocea to Present at Upcoming Scientific and Investor Conferences	GlobeNewsWire
Monday, 23 August 2021
09:56	Do Options Traders Know Something About Genocea (GNCA) Stock We Don't?	Zacks Investment Research

Ideas & Opinions

Seeking Alpha 2 Jun 2021

ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas

Frequently Asked Questions (FAQ)

What's the price of Genocea Biosciences stock today?

One share of Genocea Biosciences stock can currently be purchased for approximately $0.
When is Genocea Biosciences's next earnings date?

Unfortunately, Genocea Biosciences's (GNCA) next earnings date is currently unknown.
Does Genocea Biosciences pay dividends?

No, Genocea Biosciences does not pay dividends.
What is Genocea Biosciences's stock symbol?

Genocea Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "GNCA".
What is Genocea Biosciences's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Genocea Biosciences?

Shares of Genocea Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Genocea Biosciences's key executives?
Genocea Biosciences's management team includes the following people:
- Mr. William D. Clark M.B.A. Pres, Chief Executive Officer & Director(age: 56, pay: $821,390)
- Dr. Thomas A. Davis Chief Medical Officer(age: 61, pay: $631,720)
- Dr. Girish N. Aakalu Ph.D. Chief Bus. Officer(age: 50, pay: $536,420)
How many employees does Genocea Biosciences have?

As Jul 2024, Genocea Biosciences employs 74 workers.
When Genocea Biosciences went public?

Genocea Biosciences, Inc. is publicly traded company for more then 11 years since IPO on 5 Feb 2014.
What is Genocea Biosciences's official website?

The official website for Genocea Biosciences is genocea.com.
Where are Genocea Biosciences's headquarters?

Genocea Biosciences is headquartered at 100 Acorn Park Dr, Cambridge, MASSACHUSETTS.
How can i contact Genocea Biosciences?

Genocea Biosciences's mailing address is 100 Acorn Park Dr, Cambridge, MASSACHUSETTS and company can be reached via phone at +1 617 876 8191.

Genocea Biosciences, Inc.

genocea.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

+1 617 876 8191

100 Acorn Park Dr
Cambridge, MASSACHUSETTS 02140

CIK: 0001457612
ISIN: US3724274010
CUSIP: 372427401